{"entity":{"id":"nct03933735","kind":"trial","name":"A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma","aka":[],"tldr":"A phase 1/2 trial of TNB-383B in multiple myeloma, run by AbbVie, active and no longer recruiting.","summary":"A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT03933735 by AbbVie, with 220 participants enrolled, started 2019-06-24 and due to reach its primary completion in 2026-05. Interventions recorded: TNB-383B.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT03933735","url":"https://clinicaltrials.gov/study/NCT03933735"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT03933735","phase":"1/2","setting":"A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of TNB-383B, a Bispecific Antibody Targeting BCMA in Subjects With Relapsed or Refractory Multiple Myeloma","sponsor":"AbbVie","enrolled":220,"outcomes":[]},"route":"/trials/nct03933735/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}